Articles tagged with 'Scaffold' | BIOTRONIK

BIOTRONIK - Archive (Scaffold)

2021
18
May
2021
| 09:00 Europe/Amsterdam
New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris® Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Prof. Jan Torzewski,...
Read more
2018
24
September
2018
| 00:00 Europe/Amsterdam
Preliminary data from BIOSOLVE-IV registry shows low target lesion failure (TLF) rates of 4.3% with Magmarisa and only one case of scaffold thrombosis (after DAPT interruption before the event).1 The data presented at the TCT congress as late-brea...
Read more
14
June
2018
| 00:00 Europe/Amsterdam
Ever since its CE launch in June 2016, BIOTRONIK’s Magmaris has been implanted by more than 650 physicians in over 350 hospitals across 45 countries. As part of its Magnesium 2,000 program, a post-market evaluation program, more than 2,000 Magmaris c...
Read more
23
May
2018
| 00:00 Europe/Amsterdam
Data presented during the EuroPCR congress on the Magmaris Resorbable Magnesium Scaffold (RMS) provide further evidence on its continued safety and efficacy, also in a more complex population. Dr. Stefan Verheye, M.D., Ph.D., Senior Interventional...
Read more
2017
01
November
2017
| 00:00 Europe/Amsterdam
Data presented during the TCT congress on BIOTRONIK's Magmaris1 RMS provide further evidence on its continued safety and efficacy. Pooled 12-month data from the BIOSOLVE-II and BIOSOLVE-III clinical trials highlight high procedural success and the co...
Read more
17
May
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*. Coordinating clinical investigator Dr. Michael Haude demonstrated during a latebreaking trial session at EuroPCR 2017 that there w...
Read more